font size:
9001cc金沙以诚为本
online message
contact information
one of telephone, mobile phone number, e-mail is required
contact
tel
mobile phone
email
qq
wechat account
message
other additions
verification code

ping an-9001cc金沙以诚为本

views：

1.aulimodi raw materials and tablets received clinical approval from the nmpa on october 18, 2016.

2.omarigliptin hydrochloride raw materials and tablets received clinical approval from the nmpa on january 16, 2017.

return list previous：shionogi new drug for influenza - baloxavir (disclosed phase iii clinical trial data) next：medical insurance for flumarin®
about us
about us development history company honor
business scope
market sales technology development manufacture center
products
antibiotics digestive system medication cardiovascular and cerebrovascular medication bone and muscle medication dermatological medication nervous system medication respiratory system medication others
news release
company news notice
contact us
  • official wechat account official wechat account
  • mobile pagemobile page
  • service tel0755-2552 7000
  • business tel0755-2552 7386
linkssite mapprivacy policy
9001cc金沙以诚为本 copyright @ 2022 c&o pharmaceutical technology (holdings) limited. all rights reserved.
网站地图